<html><head></head><body><h1>Interferon Gamma</h1><p class="drug-subtitle"><b>Class:</b> Immunomodulatory Agents<br/>
- Cytokines<br/>
- Biologic Response Modifiers<br/>
<b>VA Class:</b> IM700<br/>
<b>Chemical Name:</b> N2-l-Methionyl-1-139-interferonγ (human lymphocyte protein moiety reduced)<br/>
<b>Molecular Formula:</b> C<sub>734</sub>H<sub>1166</sub>N<sub>204</sub>O<sub>216</sub>S<sub>5</sub><br/>
<b>CAS Number:</b> 98059-61-1<br/>
<b>Brands:</b> Actimmune</p><ul class="ddc-anchor-links"><li>Uses</li>
<li>Dosage</li>
<li>Cautions</li>
<li>Interactions</li>
<li>Pharmacokinetics</li>
<li>Patient advice</li>
<li>Preparations</li></ul><h2>Introduction</h2><p>Biologic response modifier; biosynthetic (recombinant DNA origin) form of endogenous human interferon gamma.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="uses">Uses for Interferon Gamma</h2><h3>Chronic Granulomatous Disease</h3><p>Reduction of the frequency and severity of serious infections in patients with chronic granulomatous disease (designated an orphan drug by FDA for this use).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;13&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;20&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;21&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;22&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Osteopetrosis</h3><p>Treatment to delay the time to disease progression in patients with severe, malignant osteopetrosis (designated an orphan drug by FDA for this use).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;13&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Idiopathic Pulmonary Fibrosis</h3><p>Interferon gamma-1b was investigated in patients with idiopathic pulmonary fibrosis† (IPF) with mild-to-moderate lung function impairment in the INSPIRE study; the study was terminated early when interim data analysis indicated lack of benefit in patients receiving the drug.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;26&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Interim analysis also indicated that 14.5% of patients receiving interferon gamma 1-b died compared with 12.7% of those receiving placebo.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;26&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Interferon gamma-1b is not approved for use in patients with IPF.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;26&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; FDA suggests that health-care professionals should discuss the results of this trial with their patients receiving the drug for IPF and carefully consider whether they should continue to receive treatment with interferon gamma-1b.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;26&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="dosage">Interferon Gamma Dosage and Administration</h2><h3>General</h3><ul>
<li>
<p>If home use is prescribed, carefully instruct patients and/or their caregivers in appropriate use; provide a puncture-resistant container for proper, safe disposal of used syringes and needles.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>If home use is prescribed, carefully instruct patients and/or their caregivers in appropriate use; provide a puncture-resistant container for proper, safe disposal of used syringes and needles.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Administration</h3><p>Administer by sub-Q injection 3 times weekly (e.g., Monday, Wednesday, Friday).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Optimum sites for sub-Q injection include right and left deltoid and anterior thigh.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>To minimize risk of flu-like syndrome, administer at bedtime and/or give acetaminophen to prevent or partially alleviate fever and headache.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Vials contain no preservative; discard any residual solution remaining in the vial after administration of the single dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Dosage</h3><p>Each mg of interferon gamma-1b is approximately equivalent to 20 million international units (equivalent to the amount that formerly was expressed as 30 million units).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>50 mcg/m<sup>2</sup> (1 million international units per m<sup>2</sup>) 3 times weekly for patients with body surface area (BSA) &gt;0.5 m<sup>2</sup> and 1.5 mcg/kg 3 times weekly for those with body surface area ≤0.5 m<sup>2</sup>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If a severe adverse reaction (e.g., flu-like symptoms) occurs, reduce dosage by 50% or discontinue drug until adverse reaction abates.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>50 mcg/m<sup>2</sup> (1 million international units per m<sup>2</sup>) 3 times weekly for patients with body surface area &gt;0.5 m<sup>2</sup> and 1.5 mcg/kg 3 times weekly for those with body surface area ≤0.5 m<sup>2</sup>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If a severe adverse reaction (e.g., flu-like symptoms) occurs, reduce dosage by 50% or discontinue drug until adverse reaction abates.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>50 mcg/m<sup>2</sup> (1 million international units per m<sup>2</sup>) 3 times weekly.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If a severe adverse reaction (e.g., flu-like symptoms) occurs, reduce dosage by 50% or discontinue drug until adverse reaction abates.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>50 mcg/m<sup>2</sup> (1 million international units per m<sup>2</sup>) 3 times weekly.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If a severe adverse reaction (e.g., flu-like symptoms) occurs, reduce dosage by 50% or discontinue drug until adverse reaction abates.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Prescribing Limits</h3><p>Safety and efficacy of dosages &gt;50 mcg/m<sup>2</sup> 3 times weekly not established.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Safety and efficacy of dosages &gt;50 mcg/m<sup>2</sup> 3 times weekly not established.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Safety and efficacy of dosages &gt;50 mcg/m<sup>2</sup> 3 times weekly not established.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Safety and efficacy of dosages &gt;50 mcg/m<sup>2</sup> 3 times weekly not established.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="cautions">Cautions for Interferon Gamma</h2><h3>Contraindications</h3><ul>
<li>
<p>Known hypersensitivity to interferon gamma-1b, products derived from <i>Escherichia coli</i>, or any ingredient in the formulation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Known hypersensitivity to interferon gamma-1b, products derived from <i>Escherichia coli</i>, or any ingredient in the formulation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Warnings/Precautions</h3><p>Acute and transient flu-like syndrome or constitutional symptoms (e.g., chills, fever)&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;20&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; that are associated with daily dosages ≥250 mcg/m<sup>2</sup> (&gt;10 times the weekly recommended dosage) may exacerbate preexisting cardiac conditions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use with caution in patients with preexisting cardiac disease (e.g., arrhythmia, CHF, symptoms of ischemia).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Possible seizures, decreased mental status, dizziness, and gait disturbance, particularly at daily dosages &gt;250 mcg/m<sup>2</sup> (&gt;10 times the weekly recommended dosage).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use with caution in patients with known seizure disorders or compromised CNS function.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Possibly severe, reversible, dose-limiting neutropenia and thrombocytopenia reported rarely.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use with caution in patients with myelosuppression and in those receiving drugs that may be myelosuppressive.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Monitor blood cell and differential counts and platelet counts prior to initiating interferon gamma-1b and at 3-month intervals during therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Proteinuria reported rarely.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Perform urinalysis and monitor appropriate blood chemistry tests prior to initiating interferon gamma-1b and at 3-month intervals during therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Possibly substantial (up to 25-fold) elevations of AST and/or ALT reported; children &lt;1 year of age most at risk (see Pediatric Use under Cautions).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Reversible with dosage reduction or interruption of therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Perform liver function tests prior to initiating interferon gamma-1b and at monthly (for children &lt;1 year of age) or 3-month intervals during therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If severe hepatic enzyme elevations occur, modify dosages.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Dosage under Dosage and Administration.)</p><p>If acute, serious hypersensitivity reactions occur, discontinue immediately and initiate appropriate therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Category C.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Not known whether interferon gamma-1b is distributed into milk; discontinue nursing or the drug.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Increased risk of elevations of AST and/or ALT in children &lt;1 year of age.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; May occur as early as 7 days after starting treatment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Hepatic Effects under Cautions.)</p><p>Possibly reversible alkaline phosphatase elevation and hypokalemia.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Common Adverse Effects</h3><p>Flu-like syndrome (e.g., headache, fever, chills, myalgia, fatigue),&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;18&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; erythema or tenderness at injection site,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; injection site hemorrhage,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; nausea,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; vomiting,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; rash.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="interactions">Interactions for Interferon Gamma</h2><p>No formal drug interaction studies to date.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Specific Drugs</h3><p>Drug</p><p>Interaction</p><p>Comments</p><p>Myelosuppressive agents</p><p>Possible additive myelosuppressive effects&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use with caution&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="pharmacokinetics">Interferon Gamma Pharmacokinetics</h2><h3>Absorption</h3><p>Following sub-Q injection, &gt;89% of dose is slowly absorbed; peak plasma concentrations attained 7 hours after dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Elimination</h3><p>5.9 hours following a single sub-Q dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2>Stability</h2><h3>Storage</h3><p>2–8°C; do not freeze.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Unentered vials may be exposed to room temperature for up to 12 hours prior to use; discard vials not returned to refrigerator or used within 12 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Avoid shaking or excessively or vigorously agitating vials.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2>Actions</h2><ul>
<li>
<p>Specific effects of interferon gamma include the enhancement of the oxidative metabolism of macrophages, antibody dependent cellular cytotoxicity (ADCC), activation of natural killer (NK) cells, and the expression of Fc receptors and major histocompatibility antigens.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>The exact mechanism(s) of action of interferon gamma-1b in patients with chronic granulomatous disease have not been fully elucidated;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; the drug appears to enhance phagocyte function to allow more effective killing of catalase-positive organisms.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Changes in superoxide levels during therapy with interferon gamma-1b do not predict efficacy and should not be used to assess patient response to therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Mechanisms of action in treatment of osteopetrosis not fully elucidated&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;12&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;15&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; but may involve enhanced superoxide production in leukocytes and osteoclasts.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Changes in superoxide levels during therapy with interferon gamma-1b do not predict efficacy and should not be used to assess patient response to therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Specific effects of interferon gamma include the enhancement of the oxidative metabolism of macrophages, antibody dependent cellular cytotoxicity (ADCC), activation of natural killer (NK) cells, and the expression of Fc receptors and major histocompatibility antigens.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>The exact mechanism(s) of action of interferon gamma-1b in patients with chronic granulomatous disease have not been fully elucidated;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; the drug appears to enhance phagocyte function to allow more effective killing of catalase-positive organisms.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Changes in superoxide levels during therapy with interferon gamma-1b do not predict efficacy and should not be used to assess patient response to therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Mechanisms of action in treatment of osteopetrosis not fully elucidated&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;12&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;15&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; but may involve enhanced superoxide production in leukocytes and osteoclasts.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Changes in superoxide levels during therapy with interferon gamma-1b do not predict efficacy and should not be used to assess patient response to therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="patient-advice">Advice to Patients</h2><ul>
<li>
<p>Importance of advising patients <i>not</i> to administer the drug until their clinician has thoroughly trained them on proper administration methods (including aseptic technique) and proper disposal of used needles and syringes.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;27&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Advise patients to notify their clinician if injection site reactions (e.g., persistent lumps, swelling, bruising, signs of infection or inflammation [pus, redness, pain]) occur.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;27&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Risk of myelosuppression and adverse hepatic effects.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of taking interferon gamma-1b as prescribed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of women informing their clinician if they are or plan to become pregnant or plan to breast-feed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as concomitant illnesses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing patients of other important precautionary information.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Cautions.)</p>
</li>
</ul><p>Importance of advising patients <i>not</i> to administer the drug until their clinician has thoroughly trained them on proper administration methods (including aseptic technique) and proper disposal of used needles and syringes.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;27&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Advise patients to notify their clinician if injection site reactions (e.g., persistent lumps, swelling, bruising, signs of infection or inflammation [pus, redness, pain]) occur.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;27&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Risk of myelosuppression and adverse hepatic effects.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of taking interferon gamma-1b as prescribed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of women informing their clinician if they are or plan to become pregnant or plan to breast-feed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as concomitant illnesses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing patients of other important precautionary information.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Cautions.)</p><h2 class="ddc-anchor-offset" id="preparations">Preparations</h2><p><i>Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.</i></p><p><i>Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.</i></p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Parenteral</p><p>Injection, for subcutaneous use</p><p>100 mcg/0.5 mL (2 million international units)</p><p>Actimmune<sup></sup></p><p>InterMune</p><p>AHFS<sup></sup> DI Essentials™. © Copyright 2021, Selected Revisions August 1, 2010. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.</p><p>† Use is not currently included in the labeling approved by the US Food and Drug Administration.</p><h2>References</h2><p>1. InterMune, Inc. Actimmune<sup></sup> (interferon gamma-1b) prescribing information. Brisbane, CA; 2009 Jan.</p><p>2. Gallin JI, Farber JM, Holland SM et al. Interferon-γ in the management of infectious diseases. <i>Ann Intern Med</i>. 1995; 123:216-24. http://www.ncbi.nlm.nih.gov/pubmed/7598304?dopt=AbstractPlus</p><p>3. Todd PA, Goa KL. Interferon gamma-1b. A review of its pharmacology and therapeutic potential in chronic granulomatous disease. <i>Drugs</i>. 1992; 43:111-22. http://www.ncbi.nlm.nih.gov/pubmed/1372855?dopt=AbstractPlus</p><p>4. Lekstrom-Himes JA, Gallin JI. Immunodeficiency diseases caused by defects in phagocytes. <i>N Engl J Med</i>. 2000; 343:1703-14. http://www.ncbi.nlm.nih.gov/pubmed/11106721?dopt=AbstractPlus</p><p>5. International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. <i>N Engl J Med</i>. 1991; 324:509-16. http://www.ncbi.nlm.nih.gov/pubmed/1846940?dopt=AbstractPlus</p><p>6. Key LL, Rodriguiz RM, Willi SM et al. Long-term treatment of osteopetrosis with recombinant-human interferon gamma. <i>N Engl J Med</i>. 1995; 332:1594-9. http://www.ncbi.nlm.nih.gov/pubmed/7753137?dopt=AbstractPlus</p><p>7. Key LL, Ries WL, Rodriguiz RM et al. Recombinant human interferon gamma therapy for osteopetrosis. <i>J Pediatr</i>. 1992; 121:119-24. http://www.ncbi.nlm.nih.gov/pubmed/1320672?dopt=AbstractPlus</p><p>8. Ahlin A, Elinder G, Palmblad J. Dose-dependent enhancement of interferon-γ on functional responses of neutrophils from chronic granulomatous disease patients. <i>Blood</i>. 1997; 89:3396-401. http://www.ncbi.nlm.nih.gov/pubmed/9129047?dopt=AbstractPlus</p><p>9. Ahlin A, Larfars G, Elinder G et al. Gamma interferon treatment of patients with chronic granulomatous disease is associated with augmented production of nitric oxide by polymorphonuclear neutrophils. <i>Clin Diag Lab Immunol</i>. 1999; 6:420-4.</p><p>10. Weening RS, Leitz GJ, Seger RA. Recombinant human interferon-gamma in patients with chronic granulomatous disease—European follow up study. <i>Eur J Pediatr</i>. 1995; 154:295-8. http://www.ncbi.nlm.nih.gov/pubmed/7607280?dopt=AbstractPlus</p><p>11. Hayden FG. Antiviral drugs (other than antiretrovirals). In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett’s principles and practices of infectious diseases. 5th ed. New York: Churchill Livingstone; 2000:460-91.</p><p>12. Madyastha PR, Yang S, Ries WL et al. IFN-gamma enhances osteoclast generation in cultures of peripheral blood from osteopetrotic patients and normalizes superoxide production. <i>J Interferon Cytokine Res</i>. 2000; 20:645-52. http://www.ncbi.nlm.nih.gov/pubmed/10926207?dopt=AbstractPlus</p><p>13. Food and Drug Administration. Orphan designations pursuant to Section 526 of the Federal Food and Cosmetic Act as amended by the Orphan Drug Act (P.L. 97-414). Rockville, MD; 2002 Oct 15. From FDA web site (http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions). Accessed 2003 Apr 14.</p><p>14. Lajeunesse D, Busque L, Menard P et al. Demonstration of an osteoblast defect in two cases of human malignant osteopetrosis. Correction of the phenotype after bone marrow transplant. <i>J Clin Invest</i>. 1996; 98:1835-42. http://www.ncbi.nlm.nih.gov/pubmed/8878435?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=507623&amp;blobtype=pdf</p><p>15. Whyte MP. Chipping away at marble-bone disease. <i>N Engl J Med</i>. 1995; 332:1639-40. http://www.ncbi.nlm.nih.gov/pubmed/7753145?dopt=AbstractPlus</p><p>16. Janeway CA, Travers P, Walport M et al eds. Immunology. 5th ed. New York, NY: Garland Publishing; 2001. From the National Library of Medicine website (http://www.ncbi.nlm.nih.gov).</p><p>17. Tramont EC, Hoover DL. Innate (general or nonspecific) host defense mechanisms. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett’s principles and practices of infectious diseases. 5th ed. New York: Churchill Livingstone; 2000:31-8.</p><p>18. Bemiller LS, Roberts DH, Starko KM et al. Safety and effectiveness of long-term interferon gamma therapy in patients with chronic granulomatous disease. <i>Blood Cells Mol Dis</i>. 1995; 21:239-247. http://www.ncbi.nlm.nih.gov/pubmed/8673477?dopt=AbstractPlus</p><p>19. Intermune. Brisbane, CA: Personal communication.</p><p>20. Errante PR, Frazão JB, Condino-Neto A. The use of interferon-gamma therapy in chronic granulomatous disease. <i>Recent Pat Antiinfect Drug Discov.</i> 2008; 3:225-30. http://www.ncbi.nlm.nih.gov/pubmed/18991804?dopt=AbstractPlus</p><p>21. Jones LBKR, McGrogan P, Flood TJ et al. Special Article: Chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registry <i>Clin Exp Immunol.</i> 2008; 152: 211–218.</p><p>22. Kobayashi S, Murayama S, Takanashi S et al. Clinical features and prognoses of 23 patients with chronic granulomatous disease followed for 21 years by a single hospital in Japan. <i>. Eur J Pediatr.</i> . 2008;167:1389-94.</p><p>23. Martire B, Rondelli R, Soresina A et al. Clinical features, long-term follow-up and outcome of a large cohort of patients with Chronic Granulomatous Disease: an Italian multicenter study. <i>Clin Immunol.</i> 2008; 126:155-64. http://www.ncbi.nlm.nih.gov/pubmed/18037347?dopt=AbstractPlus</p><p>24. Marciano BE, Wesley R, De Carlo ES et al. Long-term interferon-gamma therapy for patients with chronic granulomatous disease. <i>Clin Infect Dis.</i> 2004; 39:692-9. http://www.ncbi.nlm.nih.gov/pubmed/15356785?dopt=AbstractPlus</p><p>25. Ma HR, Mu SC, Yang YH et al. Therapeutic effect of interferon-gamma for prevention of severe infection in X-linked chronic granulomatous disease. <i>J Formos Med Assoc.</i> 2003; 102:189-92. http://www.ncbi.nlm.nih.gov/pubmed/12783137?dopt=AbstractPlus</p><p>26. Food and Drug Administration. Information for healthcare professionals–interferon gamma–1b (marketed as Actimmune) From FDA web site http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders//2007/march09.htm.</p><p>27. InterMune, Inc. Actimmune<sup></sup> (interferon gamma-1b) Information for the patient/caregiver.. Brisbane, CA; 2006 Nov.</p><h2>More about interferon gamma-1b</h2><ul class="more-resources-list more-resources-list-general">
<li>Side Effects</li>
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: interferons</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Interferon gamma-1b Injection, Subcutaneous &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(Advanced Reading)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Chronic Granulomatous Disease</li>
<li>Cutaneous T-cell Lymphoma</li>
<li>Idiopathic Pulmonary Fibrosis</li>
<li>Osteopetrosis</li>
<li>Rheumatoid Arthritis</li>
</ul><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>